Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious condition that significantly impacts patient health, contributing to high morbidity and mortality rates. The prevalence of systemic sclerosis in interstitial lung disease varies widely, ranging from 25% to 95%, depending on the detection methods employed. Despite existing treatment options such as immunosuppressive therapies, there is a significant unmet clinical need for more effective treatments to slow disease progression. The increasing focus on precision medicine and targeted therapies is expected to drive advancements in the drug pipeline, offering hope for better management and improved patient outcomes in the coming years.
Major companies involved in systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline drugs market include GlaxoSmithKline, atyr Pharma, Inc., and Prometheus Biosciences, Inc., among others.
Leading drugs currently under the pipeline include Belimumab, Tulisokibart, Mycophenolate Mofetil, and others.
The systemic sclerosis (SS) in the interstitial lung disease (ILD) drug pipeline is poised for growth due to increased focus on targeted therapies, precision medicine advancements, and the high unmet clinical need for more effective treatment options.
The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into systemic sclerosis (SS) in interstitial lung disease (ILD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for systemic sclerosis (SS) in interstitial lung disease (ILD). The systemic sclerosis (SS) in interstitial lung disease (ILD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with systemic sclerosis (SS) in interstitial lung disease (ILD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to systemic sclerosis (SS) in interstitial lung disease (ILD).
Systemic sclerosis (SS) in interstitial lung disease (ILD) is a serious complication where inflammation and scarring (fibrosis) of lung tissue result in progressive loss of lung function. The condition arises when the body's immune system mistakenly attacks healthy lung tissue, causing the buildup of fibrous tissue that interferes with normal lung function. It can significantly impair the ability to breathe, contributing to morbidity and mortality.
Systemic sclerosis (SS) in interstitial lung disease (ILD) treatment typically includes immunosuppressive medications to manage inflammation, corticosteroids to reduce immune system activity, and antifibrotic agents to slow lung tissue scarring. In recent years, novel therapies targeting fibrosis and immune modulation have been actively researched, offering hope for improved outcomes and better management of disease progression.
The prevalence of systemic sclerosis (SS) in interstitial lung disease (ILD) varies globally, ranging from 25% to 90%. Epidemiological studies highlight ethnic and regional differences, with African Americans and certain Asian populations showing a higher incidence. In comparison to Caucasians (38%), African Americans (54%) are diagnosed more commonly. Regional differences further highlight a higher prevalence in Central and Eastern Europe, as well as some parts of Asia.
This section of the report covers the analysis of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total systemic sclerosis (SS) in interstitial lung disease (ILD) clinical trials.
The drug molecule categories covered under the systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for systemic sclerosis (SS) in interstitial lung disease (ILD).
The EMR report for systemic sclerosis (SS) in interstitial lung disease (ILD) report insights to include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for systemic sclerosis (SS) in interstitial lung disease (ILD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of systemic sclerosis (SS) in interstitial lung disease (ILD) drug candidates.
A Phase 2/3 study, sponsored by GlaxoSmithKline, is investigating the efficacy and safety of belimumab in adults with systemic sclerosis-associated interstitial lung disease. The objective of this Phase 2/3 study is to evaluate belimumab's effect on lung function and extra-pulmonary manifestations. The study is expected to be completed by July 2027, with 300 participants enrolled.
The Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis-associated interstitial lung disease is being sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. This double-blind, randomized, placebo-controlled study aims to assess the safety and efficacy of Tulisokibart. The study is expected to be completed by June 2029, with an estimated 152 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Systemic Sclerosis (SS) in Interstitial Lung Disease (ILD) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for systemic sclerosis (SS) in interstitial lung disease (ILD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within systemic sclerosis (SS) in interstitial lung disease (ILD) pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share